Drug Profile
Research programme: bone fracture and spinal fusion therapy - Accelalox
Latest Information Update: 12 Sep 2023
Price :
$50
*
At a glance
- Originator Accelalox
- Class Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Fracture; Spinal disorders
Most Recent Events
- 12 Sep 2023 Discontinued - Preclinical for Fracture in USA (PO) before September 2023
- 12 Sep 2023 Discontinued - Preclinical for Spinal disorders in USA (PO) before September 2023
- 28 Aug 2020 No recent reports of development identified for preclinical development in Fracture in USA (PO)